Your Sorted CME/CE Activities

HBV Cure Initiatives: Science in Action, An Expert Review of Current Data
Accredited AMA/ANCC/ACPE Activity
HBV is a most common causes of liver cirrhosis and HCC. Curing persons with HBV infection remains elusive, despite the availablility of effective antiviral therapy. However, the urgency for an HBV cure remains an active area of research. This program will discuss key research advances in the strategies to HBV cure, pros and cons of withdrawal of therapy, and novel antiviral/immunomodulatory therapies.

Dr. Nezam Afdhal and Dr. Daryl Lau will lead each of the 15-minute segment presentations with downloadable, supporting PowerPoint slides. Each segment will be available for .25 AMA/ANCC/ACPE credit/contact hour based on confirmed participation and the completion of an evaluation and post-test.
Review the activity to claim AMA, ANCC, or ACPE credit/contact hour(s) after completion of the brief Post-Test/Evaluation.













Nezam Afdhal, MD, DSc Nezam Afdhal, MD, DSc
Chief, Division of Gastroenterology, Hepatology and Nutrition
Beth Israel Deaconess Medical Center
Charlotte and Irving Rabb Professor of Medicine
Harvard Medical School
Daryl Lau, MD, MPH Daryl Lau, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Director, Translational Liver Research
Beth Israel Deaconess Medical Center

20
Supported by an independent educational grant from Gilead Sciences Medical Affairs

Launch Date: January 4, 2022
Release Date: December 16, 2021
Expiration Date: December 31, 2022

December 31, 2022
Mini Module
7285
HBV.CureInitiatives_WebBanner(1150).gif
LiverDisease